Aerie Pharmaceuticals to Participate in Two Investor Conferences in February

Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that company management will present an overview of the company at the following conferences in February.

• 17th Annual BIO CEO & Investor Conference
  • Presenter: Richard Rubino, Chief Financial Officer
  • Presentation Date: Tuesday, February 10, 2015
  • Presentation Time: 1:00pm E.T.
• RBC Capital Markets Global Healthcare Conference
  • Presenter: Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board
  • Presentation Date: Tuesday, February 24, 2015
  • Presentation Time: 10:00am E.T.

The presentations will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.

About Aerie Pharmaceuticals

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company is conducting two Phase 3 registration trials in the United States, named "Rocket 1" and "Rocket 2," where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for Rhopressa™ compared to timolol, along with a third Phase 3 registration safety-only trial, named "Rocket 3," in Canada.

In June 2014, the Company also completed a Phase 2b clinical trial where Roclatan™ met the primary efficacy endpoint, demonstrating the statistical superiority of Roclatan™ to each of its components. Roclatan™ is a fixed-dose combination of Rhopressa™ with latanoprost, the market-leading PGA, and we believe, if approved, has the potential to provide a greater IOP-lowering effect than any currently approved glaucoma product. Phase 3 registration trials for Roclatan™ are expected to commence in mid-2015. Preparatory steps for these trials are in progress and on schedule.